If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In August 2008, Helton was diagnosed with a degenerative back condition, putting his health and ability to continue play in question. On May 19, 2009, Helton got his 2,000th hit, a single, during an 8–1 road loss to the Atlanta Braves. On July 22, Helton hit his 500th career double in a 4–3 home victory over the Arizona Diamondbacks. He became the 50th player in MLB history to hit 500 career doubles and the fastest to do since 1954. Helton also joined Babe Ruth, Stan Musial, Lou Gehrig and Ted Williams as the only players in MLB history to have at least 500 doubles, 320 home runs and a .325 batting average for a career. On March 11, 2010, Helton signed a two-year, $9.9 million contract extension, which ran through the 2013 season. Helton's degenerative back condition sent him back to the disabled list in July. He returned from the DL in August and hit .256 with 8 home runs and 37 RBI for the season. After the season, Helton said he would return to the Rockies in 2011, dispelling rumors of a possible retirement. On February 15, 2011, Helton announced his intention to play baseball for three more years, preferably for the Rockies. On June 30 he played his 2,000th career game. In 2012, Helton continued to deal with what was by now a chronic health issue. On April 14, he drove a 2-run walk-off home run through heavy rain, the seventh walk-off of his career. On July 13, Helton was placed on the 15-day disabled list due to inflammation in his right hip. He had played 63 games to that point, and was batting .235.
Carroll, J. T. (1975). Ireland in the War Years 1939–1945. David and Charles. ISBN 9780844805658. Coogan, Tim Pat (1993). De Valera: Long Fellow, Long Shadow. London: Hutchinson. ISBN 9780091750305. published as Eamon de Valera: The Man Who Was Ireland (New York, 1993) Coogan, Tim Pat (1990). Michael Collins. Hutchinson. ISBN 0-09-174106-8. Corcoran, Donal. "Public policy in an emerging state: The Irish Free State 1922-25." Irish Journal of Public Policy 1.1 (2009). online Dwyer, T. Ryle (2006). Big Fellow, Long Fellow: A Joint Biography of Collins and De Valera. Gill Books. ISBN 0717140849. excerpt and text search Dwyer, T. Ryle (1982). De Valera's Finest Hour 1932–59. Fanning, Ronan. Éamon de Valera: A Will to Power (2016) Foster, R. F. Modern Ireland, 1600-1972 (1989) online Girvin, Brian. "Beyond Revisionism? Some Recent Contributions to the Study of Modern Ireland." The English Historical Review 124#506, 2009, pp. 94–107. online Gwynn, Denis. The Irish Free State, 1922-1927 (Macmillan 1928); detailed coverage.online Keown, Gerard. First of the Small Nations: The Beginnings of Irish Foreign Policy in the Inter-war Years, 1919-1932 (Oxford University Press, 2016). online Kissane, Bill. "Eamon De Valera and the Survival of Democracy in Inter-War Ireland". Journal of Contemporary History (2007). 42 (2): 213–226. online Lee, J. J. Ireland, 1912-1985: politics and society (Cambridge University Press, 1989) online. McCardle, Dorothy (January 1999). The Irish Republic. Wolfhound Press. ISBN 0-86327-712-8. O'Halpin, Eunan.
Coagulation factors (II, VII, IX, X), as well as anticoagulation proteins (C, S, Z). These Gla-proteins are synthesized in the liver and play an important role in blood homeostasis. Osteocalcin. This non-collagenous protein is secreted by osteoblasts and plays an essential role in the formation of mineral in bone. Matrix gla protein (MGP). This calcification inhibitory protein is found in numerous body tissues, but its role is most pronounced in cartilage and in arterial vessel walls. Growth arrest-specific protein 6 (GAS6). GAS6 is secreted by leucocytes and endothelial cells in response to injury and helps in cell survival, proliferation, migration, and adhesion. Proline-rich Gla-proteins (PRGP), transmembrane Gla-proteins (TMG), Gla-rich protein (GRP) and periostin. Their precise functions are still unknown.
"The cyclization of peptides and depsipeptides", Volume 9, Issue 8, Aug 2003, Pages: 471–501, Davies JS "Antibacterial peptides isolated from insects", Volume 6, Issue 10, Oct 2000, Pages: 497–511, Otvos L "Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: Binding sites and implications for Alzheimer's disease", Volume 10, Issue 5, May 2004, Pages: 229–248, Verdier Y, Zarandi M, Penke B
Sources: en.wikipedia.org
== Bibliography == McNeill, A; Brose, LS; Calder, R; Bauld, L; Robson, D (February 2018). "Evidence review of e-cigarettes and heated tobacco products 2018" (PDF). UK: Public Health England. pp. 1–243. Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (January 2018). Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (eds.). Public Health Consequences of E-Cigarettes (PDF). National Academies of Sciences, Engineering, and Medicine (National Academies Press). pp. 1–774. Bibcode:2018nap..book24952N. doi:10.17226/24952. ISBN 978-0-309-46834-3. PMID 29894118. McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). UK: Public Health England. pp. 1–113. "Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS)" (PDF). World Health Organization WHO. August 2016. pp. 1–11. Wilder, Natalie; Daley, Claire; Sugarman, Jane; Partridge, James (April 2016). "Nicotine without smoke: Tobacco harm reduction". UK: Royal College of Physicians. pp. 1–191. "State Health Officer's Report on E-Cigarettes: A Community Health Threat" (PDF). California Tobacco Control Program. California Department of Public Health. January 2015. pp. 1–21. This article incorporates text from this source, which is in the public domain.
=== Differential diagnoses === The muscle weakness that worsens with activity (abnormal muscle fatigue) in myasthenia gravis is a symptom shared by other neuromuscular diseases. Most of the metabolic myopathies, such as McArdle disease (GSD-V), have abnormal muscle fatigue rather than fixed muscle weakness. Also, like myasthenia gravis, exercise intolerance in McArdle disease improves with regular physical activity (performed safely using activity adaptations such as getting into second wind, the "30 for 80 rule," and "six second rule"). A small minority of people with McArdle disease also have the comorbidity of ptosis (drooping upper eyelid). Late-onset GSD-II (Pompe disease) and GSD-XV also have muscle weakness or fatigue with comorbidities of ptosis and ophthalmoplegia; as do many of the mitochondrial myopathies. Other diseases that involve abnormal muscle fatigue (which may be described as exercise-induced muscle weakness, reversible muscle weakness, or muscle weakness that improves with rest) include: endocrine myopathies (such as Hoffman syndrome), Tubular aggregate myopathy (TAM), ischemia (such as intermittent claudication, popliteal artery entrapment syndrome, and chronic venous insufficiency), and poor diet or malabsorption diseases that lead to vitamin D deficiency (osteomalic myopathy). Although limb-girdle muscular dystrophies (LGMDs) involve fixed muscle weakness, LGMDR8 also involves muscle fatigue; as do some limb-girdle muscular dystrophy-dystroglycanopathies such as MDDGC3 (a.k.a. LGMDR15 and LGMD2O).
1993/584) National Blood Authority (Establishment and Constitution) Order 1993 (S.I. 1993/585) National Blood Authority Regulations 1993 (S.I. 1993/586) Central Blood Laboratories Authority (Revocation) Order 1993 (S.I. 1993/587) Nurses, Midwives and Health Visitors Act 1992 (Commencement No. 1) Order 1993 (S.I. 1993/588) Registration of Births, Deaths and Marriages (Fees) (Amendment) (No. 2) Order 1993 (S.I. 1993/589) United Kingdom Central Council for Nursing, Midwifery and Health Visiting (Term of Office of Members) Order 1993 (S.I. 1993/590) Recovery of Maintenance (United States of America) Order 1993 (S.I. 1993/591) Social Security (Northern Ireland) Order 1993 (S.I. 1993/592) Reciprocal Enforcement of Maintenance Orders (Hague Convention Countries) Order 1993 (S.I. 1993/593) Reciprocal Enforcement of Maintenance Orders (Republic of Ireland) Order 1993 (S.I. 1993/594) European Communities (Designation) Order 1993 (S.I. 1993/595) Veterinary Surgeons Qualifications (EEC Recognition) (Amendment) Order 1993 (S.I. 1993/596) Home Guard (Amendment) Order 1993 (S.I. 1993/597) Naval, Military and Air Forces etc. (Disablement and Death) Service Pensions Amendment Order 1993 (S.I. 1993/598) Continental Shelf (Designation of Areas) Order 1993 (S.I. 1993/599)
Earlier estimates for snakebite vary from 1.2 to 5.5 million, with 421,000 to 2.5 million being envenomings, and causing 20,000 to 125,000 deaths. More recent modelling estimates that in 2019, about 63,400 people died globally from snakebite, with 51,100 of these deaths happening in India. Since reporting is not mandatory in much of the world, the data on the frequency of snakebites is not precise. Many people who survive bites have permanent tissue damage caused by venom, leading to disability. Most snake envenomings and fatalities occur in South Asia, Southeast Asia, and sub-Saharan Africa, with India reporting the most snakebite deaths of any country. Available evidence on the effect of climate change on the epidemiology of snakebite is limited but it is expected that there will be a geographic shift in the risk of snakebite: northwards in North America and southwards in South America and Mozambique, and increase in the incidence of bite in Sri Lanka. Most snakebites are caused by non-venomous snakes. Of the roughly 3,000 known species of snake found worldwide, only 15% are considered dangerous to humans. Snakes are found on every continent except Antarctica. The most diverse and widely distributed snake family, the colubrids, has approximately 700 venomous species, but only five genera—boomslangs, twig snakes, keelback snakes, green snakes, and slender snakes—have caused human fatalities. Worldwide, snakebites occur most frequently in the summer season when snakes are active and humans are outdoors.
Its Estey Hall was the first building constructed for the higher education of Black women, and Leonard Medical Center was the first four-year medical school in the country for African Americans. In 1867, Episcopal clergy founded St. Augustine's College for the education of freedmen. The biracial Reconstruction legislature created new welfare institutions: in 1869, it approved the United States' first school for blind and deaf Black people, to be located in Raleigh. In 1874, the federal government constructed the Federal Building in Raleigh, the first federal government project in the Southern U.S. following the Civil War. In 1880, the newspapers News and Observer combined to form The News & Observer. It continues to be Raleigh's primary daily newspaper. The North Carolina College of Agriculture and Mechanic Arts, now known as North Carolina State University, was founded as a land-grant college in 1887. The city's Rex Hospital opened in 1889 and included the state's first nursing school. The Baptist Women's College, now known as Meredith College, opened in 1891, and in 1898, The Academy of Music, a private music conservatory, was established. In the late nineteenth century, two Black Congressmen were elected from North Carolina's 2nd district, the last in 1898. George Henry White sought to promote civil rights for Black citizens and to challenge efforts by White Democrats to reduce Black voting by new discriminatory laws. He and his allies were unsuccessful.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.